Industry
Biotechnology
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Loading...
Open
31.68
Mkt cap
1.8B
Volume
383K
High
32.55
P/E Ratio
15.35
52-wk high
41.61
Low
31.50
Div yield
N/A
52-wk low
28.14
Portfolio Pulse from
December 04, 2024 | 12:45 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.